America’s overreliance on offshore manufacturing has most recently raised concerns as we witnessed China’s overwhelming influence on our access to essential pharmaceuticals and healthcare goods. While the pandemic has largely proven the need for more onshoring strategies to address future crises, businesses’ buy-in to return to U.S. soil will only be realized through incentivization.
